Journal of veterinary pharmacology and therapeutics最新文献_第5页

Pharmacokinetics of intraarticular liposomal amphotericin B in goats (Capra aegagrus hircus) 山羊（Capra aegagrus hircus）关节内脂质体两性霉素 B 的药代动力学。

IF 1.5 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-04-01 DOI: 10.1111/jvp.13442

Joe S. Smith, Grace D. Malla, Jessica D. Garcia, Jessica E. Gebert, Charlene V. Noll, Pierre-Yves Mulon, Heather K. Knych

{"title":"Pharmacokinetics of intraarticular liposomal amphotericin B in goats (Capra aegagrus hircus)","authors":"Joe S. Smith, Grace D. Malla, Jessica D. Garcia, Jessica E. Gebert, Charlene V. Noll, Pierre-Yves Mulon, Heather K. Knych","doi":"10.1111/jvp.13442","DOIUrl":"10.1111/jvp.13442","url":null,"abstract":"Lameness is a significant welfare concern in goats. Amphotericin B is used via intraarticular (IA) administration in models to study experimentally induced lameness in large animals. The main objective of this study was to estimate plasma pharmacokinetic (PK) parameters for amphotericin B in goats after a single IA administration. Liposomal amphotericin B was administered to ten Kiko-cross goats at a dose of 10 mg total (range: 0.34–0.51 mg/kg) via IA administration into the right hind lateral distal interphalangeal joint. Plasma samples were collected over 96 h. Amphotericin B concentrations were measured via liquid chromatography/mass spectrometry (LC–MS/MS). A non-compartmental analysis was used to derive PK parameters. Following single IA administration, maximum plasma concentration was estimated at 54.6 ± 16.5 ng/mL, and time to maximum concentration ranged from 6 to 12 h. Elimination half-life was estimated at 30.9 ± 16.5 h, and mean residence time was 45.1 ± 10.4 h. The volume of distribution after IA administration was 13.3 ± 9.4 L/kg. The area under the curve was 1481 ± 761 h*ng/mL. The achieved maximum concentration was less than the observed concentrations for other species and routes of administration. Further research is needed into the pharmacodynamics of IA liposomal amphotericin B in goats to determine specific research strategies.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140336073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative disposition kinetics of oral deracoxib in sheep and goats 绵羊和山羊口服德拉克西布的处置动力学比较。

IF 1.5 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-28 DOI: 10.1111/jvp.13444

Charbel Fadel, Beata Łebkowska-Wieruszewska, Andrzej Lisowski, Firas Serih, Amnart Poapolathep, Mario Giorgi

{"title":"Comparative disposition kinetics of oral deracoxib in sheep and goats","authors":"Charbel Fadel, Beata Łebkowska-Wieruszewska, Andrzej Lisowski, Firas Serih, Amnart Poapolathep, Mario Giorgi","doi":"10.1111/jvp.13444","DOIUrl":"10.1111/jvp.13444","url":null,"abstract":"This study investigates the pharmacokinetics (PK) of deracoxib (DX), a selective COX-2 inhibitor, in sheep and goats following a single oral dose. DX, approved for dogs, holds potential as an alternative NSAID in small ruminants, particularly in light of heightened concern regarding abomasal ulceration. The study employed an oral administration of DX at a dose of 150 mg/head (sheep and goats), and plasma concentrations were determined after validating a high-performance liquid chromatography method, coupled to a UV detector. The PK parameters, including maximum plasma concentration (C\u0000 max), time to reach C\u0000 max (T\u0000 max), elimination half-life (t\u0000 1/2), and area under the curve (AUC), were evaluated through non-compartmental analysis. Results showed detectable DX in plasma up to 48 h, with no observed adverse effects. No significant differences in any PK parameters were noted between sheep and goats. Notably, t\u0000 1/2 values were relatively long, at 16.66 h for sheep and 22.86 h for goats. Despite the fact that both species exhibited comparable drug exposure, high individual variability was noted within each species, suggesting to take into account individual variations in response to DX treatment, rather than species-specific considerations. Additional research involving pharmacodynamics and multiple-dose studies is warranted to comprehensively assess the profile of DX in these species.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140306027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetics of subcutaneous ketamine administration via the Omnipod® system in dogs 通过 Omnipod® 系统在狗身上皮下注射氯胺酮的药代动力学。

IF 1.5 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-27 DOI: 10.1111/jvp.13440

Claudia Colón, Peter Early, Karen Muñana, Natasha Olby, Christopher Mariani, Shelby Mancini, Gilad Fefer, Zhong Li, Jessica Briley, Kate Bailey, Duncan Lascelles, Kristen Messenger

{"title":"Pharmacokinetics of subcutaneous ketamine administration via the Omnipod® system in dogs","authors":"Claudia Colón, Peter Early, Karen Muñana, Natasha Olby, Christopher Mariani, Shelby Mancini, Gilad Fefer, Zhong Li, Jessica Briley, Kate Bailey, Duncan Lascelles, Kristen Messenger","doi":"10.1111/jvp.13440","DOIUrl":"10.1111/jvp.13440","url":null,"abstract":"Ketamine is an injectable anesthetic agent with analgesic and antidepressant effects that can prevent maladaptive pain. Ketamine is metabolized by the liver into norketamine, an active metabolite. Prior rodent studies have suggested that norketamine is thought to contribute up to 30% of ketamine's analgesic effect. Ketamine is usually administered as an intravenous (IV) bolus injection or continuous rate infusion (CRI) but can be administered subcutaneously (SC) and intramuscularly (IM). The Omnipod® is a wireless, subcutaneous insulin delivery device that adheres to the skin and delivers insulin as an SC CRI. The Omnipod® was used in dogs for postoperative administration of ketamine as a 1 mg/kg infusion bolus (IB) over 1 hour (h). Pharmacokinetics (PK) showed plasma ketamine concentrations between 42 and 326.1 ng/mL. The median peak plasma concentration was 79.5 (41.9–326.1) ng/mL with a Tmax of 60 (30–75) min. After the same infusion bolus, the corresponding norketamine PK showed plasma drug concentrations between 22.0 and 64.8 ng/mL. The median peak plasma concentration was 43.0 (26.1–71.8) ng/mL with a median Tmax of 75 min. The median peak ketamine plasma concentration exceeded 100 ng/mL in dogs for less than 1 h post infusion. The Omnipod® system successfully delivered subcutaneous ketamine to dogs in the postoperatively.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13440","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140306028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal release site for delayed release and gelatin capsules in healthy dogs 健康狗胃肠道释放缓释胶囊和明胶胶囊的部位。

IF 1.5 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-22 DOI: 10.1111/jvp.13439

Charles B. Stone, Adam J. Rudinsky, Rebecca J. Urion, Simone B. March, Jenessa A. Winston

{"title":"Gastrointestinal release site for delayed release and gelatin capsules in healthy dogs","authors":"Charles B. Stone, Adam J. Rudinsky, Rebecca J. Urion, Simone B. March, Jenessa A. Winston","doi":"10.1111/jvp.13439","DOIUrl":"10.1111/jvp.13439","url":null,"abstract":"Gelatin capsules deliver their contents to the stomach, while delayed-release (DR) capsules are designed to allow delivery to the small intestine. This study evaluated the gastrointestinal release site of DR capsules in six healthy adult dogs compared to gelatin capsules. Both gelatin and DR capsules were filled with barium-impregnated polyethylene spheres (BIPS™), and following enteral administration, release site was assessed using abdominal radiographs at baseline, immediately after ingestion, 15 min post-ingestion, 30 min post-ingestion, and then every 30 min thereafter. The evaluated phases included fasted conditions (phase 1, n = 6), increased meal size (phase 2, n = 2), double encapsulation (phase 3, n = 2), and altered capsule size (phase 4, n = 1). The released site was the stomach in all phases for both capsule types. In phase 1, DR capsules had a significantly prolonged time (median 60 min, range 60–90) to release BIPS™ compared to gelatin capsules (15 min, range 15–30; p = .03). In phase 2 (full meal size), 3 (double encapsulation), and 4 (smaller capsule size) pilot studies, release time was prolonged but still occurred in the stomach. This is similar to the release site for gelatin capsules but differs from the release site for DR capsules in people. This has implications for pharmacologic outcomes for products that are affected by gastric physiology (e.g. fecal microbiota transplantation). Based on this pilot data, clinicians and researchers should not assume DR capsules will allow for intestinal delivery of contents in dogs. Future studies should be conducted on larger and varied populations of dogs.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13439","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140194084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic characteristics of florfenicol in green sea turtles (Chelonia mydas) and hawksbill sea turtles (Eretmochelys imbricata) after intramuscular administration 绿海龟（Chelonia mydas）和玳瑁（Eretmochelys imbricata）肌肉注射氟苯尼考的药代动力学特征。

IF 1.5 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-22 DOI: 10.1111/jvp.13441

Pandaree Sitthiangkool, Amnart Poapolathep, Thanaphan Chomcheun, Oranee Jongkolpath, Kraisiri Khidkhan, Narumol Klangkaew, Napasorn Phaochoosak, Mario Giorgi, Saranya Poapolathep

{"title":"Pharmacokinetic characteristics of florfenicol in green sea turtles (Chelonia mydas) and hawksbill sea turtles (Eretmochelys imbricata) after intramuscular administration","authors":"Pandaree Sitthiangkool, Amnart Poapolathep, Thanaphan Chomcheun, Oranee Jongkolpath, Kraisiri Khidkhan, Narumol Klangkaew, Napasorn Phaochoosak, Mario Giorgi, Saranya Poapolathep","doi":"10.1111/jvp.13441","DOIUrl":"10.1111/jvp.13441","url":null,"abstract":"The pharmacokinetics of florfenicol (FFC) in green sea and hawksbill sea turtles were evaluated following intramuscular (i.m.) administration at two different dosages of 20 or 30 mg/kg body weight (b.w.). This study (longitudinal design) used 5 green sea and 5 hawksbill sea turtles for the two dosages. Blood samples were collected at assigned times up to 168 h. FFC plasma samples were analyzed using validated high-performance liquid chromatography equipped with diode array detection. The pharmacokinetic analysis was performed using a non-compartment approach. The FFC plasma concentrations increased with the dosage. The elimination half-life was similar between the treatment groups (range 19–25 h), as well as the plasma protein binding (range 18.59%–20.65%). According to the surrogate PK/PD parameter (T > MIC, 2 μg/mL), the 20 and 30 mg/kg dosing rates should be effective doses for susceptible bacterial infections in green sea and hawksbill sea turtles.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140194085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to: Letter to the Editor from Malik et al.: Acute kidney injury following subcutaneous meloxicam administration 回复Malik等人致编辑的信：皮下注射美洛昔康后的急性肾损伤。

IF 1.3 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-10 DOI: 10.1111/jvp.13438

Alex Krekis, Jonathan N. King, Duncan D'Arcy-Howard, Nadene Stapleton, Jonathan Elliott, Ludovic Pelligand

引用次数: 0

Pharmacokinetic report: Pharmacokinetics of a single oral dose of gabapentin in goats (Capra hircus) 药代动力学报告：山羊（Capra hircus）单次口服加巴喷丁的药代动力学。

IF 1.5 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-01 DOI: 10.1111/jvp.13436

Michael D. Kleinhenz, Darian Davis, Mikaela M. Weeder, Alyssa Leslie, Emily J. Reppert, Kushan Kompalage, Ryan Tucker, Johann F. Coetzee

{"title":"Pharmacokinetic report: Pharmacokinetics of a single oral dose of gabapentin in goats (Capra hircus)","authors":"Michael D. Kleinhenz, Darian Davis, Mikaela M. Weeder, Alyssa Leslie, Emily J. Reppert, Kushan Kompalage, Ryan Tucker, Johann F. Coetzee","doi":"10.1111/jvp.13436","DOIUrl":"10.1111/jvp.13436","url":null,"abstract":"Gabapentin is used in goats to treat chronic pain associated with lameness. However, pharmacokinetic data and clinical effectiveness trials are lacking. The objective of the study was to describe the pharmacokinetics of gabapentin in goats following a single oral dose. Six Spanish-crossbred goats were enrolled. Each goat was administered gabapentin at a target dose of 15 mg/kg per os. Serial blood samples were collected out to 60 h post-gabapentin administration for plasma gabapentin concentration determination. Plasma samples were analyzed for gabapentin concentration using ultra-high-pressure liquid chromatography coupled with mass spectroscopy. Individual animal pharmacokinetic outcomes were determined using non-compartmental analysis. Gabapentin was detectable in the plasma of all goats at 60 h post-administration. The mean (±SD) Cmax was 2.01 ± 0.62 μg/mL which occurred at 8.47 ± 1.9 h. The mean terminal half-life (T1/2) and mean resident time were determined to be 8.52 ± 1.8 and 18.7 ± 4.0 h, respectively. This study indicates gabapentin is absorbed from the gastrointestinal tract of goats. Further research is needed to determine an optimal dose for clinical efficacy in goats.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.13436","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140012794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the Editor: Acute kidney injury following subcutaneous meloxicam administration 致编辑的信：皮下注射美洛昔康后的急性肾损伤。

IF 1.3 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-03-01 DOI: 10.1111/jvp.13437

Richard Malik, Matthew K. Wun, Terence King, Rachel Korman

引用次数: 0

Florfenicol urinary excretion and its potential for treating canine urinary tract infections 氟苯尼考的尿排泄及其治疗犬尿路感染的潜力。

IF 1.3 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-02-29 DOI: 10.1111/jvp.13434

Kate S. KuKanich, Elayna E. Anderson, Astrid D. Carcamo Tzic, Butch KuKanich

{"title":"Florfenicol urinary excretion and its potential for treating canine urinary tract infections","authors":"Kate S. KuKanich, Elayna E. Anderson, Astrid D. Carcamo Tzic, Butch KuKanich","doi":"10.1111/jvp.13434","DOIUrl":"10.1111/jvp.13434","url":null,"abstract":"The canine urinary excretion of florfenicol was evaluated to explore its potential for treating urinary tract infections. Nine healthy male intact purpose-bred Beagles and four healthy client-owned dogs each received a single oral dose of florfenicol 20 mg/kg (300 mg/mL parenteral solution) with food. All voluntary urinations were collected for 12 h. Although florfenicol is reportedly bitter tasting, 7/9 Beagles and 4/4 client-owned dogs completely ingested the florfenicol and were enrolled; salivation (n = 1) and headshaking (n = 3) were observed. The last measured urine florfenicol concentrations were variable: Beagles (0.23–3.19 mcg/mL), Pug (3.01 mcg/mL) English Setter (21.29 mcg/mL), Greyhound (32.68 mcg/mL), and Standard Poodle (13.00 mcg/mL). Urine half-life was similar for the Beagles and the Pug, 0.75–1.39 h, whereas the half-life was 1.70–1.82 h for the English Setter, Greyhound, and Standard Poodle. Larger breed dogs exceeded 8 mcg/mL florfenicol (wild-type cutoff) in their urine at 12 h, whereas the Beagles and Pug had <8 mcg/mL; it is unclear if this is an individual, breed, or size difference. These data suggest oral florfenicol may need to be administered q6-12h for canine urinary tract infections, but further data are needed (more enrolled dogs, multiple-dose regimens) before considering clinical trials or breed-specific differences.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic evaluation of oral deracoxib in geese (Anser anser domesticus) 鹅（Anser anser domesticus）口服德拉克西布的药代动力学评估。

IF 1.3 4区农林科学

Journal of veterinary pharmacology and therapeutics Pub Date : 2024-02-29 DOI: 10.1111/jvp.13435

Charbel Fadel, Beata Łebkowska-Wieruszewska, Amnart Poapolathep, Firas Serih, Krzysztof Bourdo, Mario Giorgi

{"title":"Pharmacokinetic evaluation of oral deracoxib in geese (Anser anser domesticus)","authors":"Charbel Fadel, Beata Łebkowska-Wieruszewska, Amnart Poapolathep, Firas Serih, Krzysztof Bourdo, Mario Giorgi","doi":"10.1111/jvp.13435","DOIUrl":"10.1111/jvp.13435","url":null,"abstract":"The integration of pain management in veterinary practice, driven by heightened animal welfare concerns, extends to avian species where subtle and nonspecific behavioral signs pose challenges. Given that safety concerns with classical NSAIDs highlight the need for more targeted alternatives in birds, this study explores the pharmacokinetic (PK) properties of Deracoxib (DX), a COX-2 selective NSAID approved for use in dogs, following a single oral administration in geese. Six healthy female geese received 4 mg/kg DX. Blood was drawn from the left wing vein to heparinized tubes at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 24 h. Plasma DX concentrations were measured using HPLC coupled to an UV detector, and the data were pharmacokinetically analyzed using PKanalix™ software in a non-compartmental approach. The results indicated a terminal half-life of 6.3 h and a Tmax of 1 h, with no observed adverse effects. While refraining from claiming absolute safety based on a single dose, it is worth highlighting that further safety studies for DX in geese are warranted, suggesting a possibility for intermittent use. In addition, drawing conclusions on efficacy and suitability awaits further research, particularly in understanding COX-2 selectivity and protein binding characteristics specific to geese.","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0